PT. RICHMOND, Calif., Sept. 28 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs, today announced that Glenn A. Oclassen, President and Chief Executive Officer, is scheduled to present at the 2007 BIO Investor Forum at the Palace Hotel in San Francisco on Thursday, October 11, 2007 at 3:00 PM Pacific Time.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. The company's development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. Transcept's lead compound, Intermezzo(TM) (zolpidem tartrate lozenge), is a low dose formulation of zolpidem that is currently in late phase 3 clinical trials for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. TO-2060 is a novel, fixed-combination dose of olanzapine and ondansetron that is being evaluated for the treatment of dopamine associated psychiatric disorders (DAPD). TO-2060 is currently the subject of an initial proof of concept trial in the treatment of alcohol use disorder (AUD). For more information, please visit the Company's website at: http://www.transcept.com.
|SOURCE Transcept Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved